Appointments to SCRI's drug development programme
This article was originally published in Scrip
Sarah Cannon Research Institute has promoted Dr Jeffrey Infante to director of drug development in Nashville, US, while Dr Howard Burris will assume the role of executive director for the overall drug development programme. Dr Burris, SCRI's CMO, will provide executive oversight of the drug development programmes in Nashville, Oklahoma, Florida and London. Dr Infante previously served as associate director of the Nashville based drug development programme.